Foster Victor Wealth Advisors LLC Has $726,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Foster Victor Wealth Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 29.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 771 shares of the company’s stock after buying an additional 175 shares during the quarter. Foster Victor Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $726,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LLY. Gradient Investments LLC lifted its position in shares of Eli Lilly and Company by 27.9% during the 2nd quarter. Gradient Investments LLC now owns 513 shares of the company’s stock worth $464,000 after buying an additional 112 shares in the last quarter. Insight Wealth Partners LLC grew its position in Eli Lilly and Company by 184.2% during the second quarter. Insight Wealth Partners LLC now owns 810 shares of the company’s stock valued at $734,000 after acquiring an additional 525 shares during the last quarter. Brookstone Capital Management grew its holdings in shares of Eli Lilly and Company by 9.0% in the second quarter. Brookstone Capital Management now owns 30,940 shares of the company’s stock worth $28,019,000 after purchasing an additional 2,558 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Eli Lilly and Company by 7.4% in the second quarter. Blue Trust Inc. now owns 53,033 shares of the company’s stock worth $48,015,000 after purchasing an additional 3,649 shares during the last quarter. Finally, Old Port Advisors boosted its holdings in Eli Lilly and Company by 4.8% in the second quarter. Old Port Advisors now owns 1,266 shares of the company’s stock valued at $1,146,000 after acquiring an additional 58 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.0 %

Shares of LLY traded down $9.46 during trading hours on Friday, hitting $922.12. 2,364,894 shares of the stock were exchanged, compared to its average volume of 3,096,824. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The firm has a market capitalization of $876.39 billion, a P/E ratio of 135.81, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. The business has a 50-day moving average of $878.93 and a 200-day moving average of $805.16. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $966.10.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Barclays upped their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Finally, Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $956.88.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.